The T-Cell therapy developer, based on research at Baylor College of Medicine, has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.
AlloVir, a US-based cell therapy developer spun out of Baylor College of Medicine, has received $120m in a series B round that included pharmaceutical firm Gilead Sciences.
The round was led by financial services and investment group Fidelity Management and Research, and also featured cell and gene therapy company builder ElevateBio, F2 Ventures, Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners Co-investment Fund.
Founded in 2013 and formerly known as ViraCyte, AlloVir is developing cell therapies…
